Related Experiment Video
Updated: Aug 6, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Nonpeptide inhibitors of measles virus entry
Aiming Sun1, Andrew Prussia, Weiqiang Zhan
1Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, Georgia 30322, USA.
Abstract:
Measles virus (MV) is one of the most infectious pathogens known. Despite the existence of a vaccine, over 500,000 deaths/year result from MV or associated complications. Anti-measles compounds could conceivably reverse these statistics. Previously, we described a homology model of the MV fusion protein trimer and a putative binding site near the head-neck region. The resulting model permitted the identification of two nonpeptidic entry inhibitors. Here, we present the design, synthesis, and bioevaluation of several series of fusion inhibitors and describe their structure-activity relationships (SAR). Five simply substituted anilides show low-microM blockade of the MV, one of which (AS-48) exhibits IC50 = 0.6-3.0 microM across a panel of wild-type MV strains found in the field. Molecular field topology analysis (MFTA), a 2D QSAR approach based on local molecular properties (atomic charges, hydrogen-bonding capacity and local lipophilicity), applied to the anilide series suggests structural modifications to improve potency.
Insights
New anti-measles compounds offer hope against measles virus (MV) infections. Researchers identified potent fusion inhibitors, like AS-48, demonstrating low-micromolar activity against wild-type MV strains.
Area of Science:
- Virology
- Medicinal Chemistry
Background:
- Measles virus (MV) is a highly contagious pathogen responsible for significant mortality and morbidity globally.
- Existing vaccines, while effective, do not prevent all infections or complications, highlighting the need for antiviral therapies.
Purpose of the Study:
- To design, synthesize, and evaluate novel nonpeptidic fusion inhibitors targeting the measles virus.
- To explore the structure-activity relationships (SAR) of identified inhibitor series to guide further optimization.
Main Methods:
- Utilized a homology model of the MV fusion protein to identify a putative binding site.
- Designed and synthesized several series of substituted anilides as potential MV fusion inhibitors.
- Bioevaluated compounds using assays to determine their inhibitory concentration (IC50) against wild-type MV strains.
- Applied Molecular Field Topology Analysis (MFTA) for quantitative structure-activity relationship (QSAR) analysis.
Main Results:
- Identified five substituted anilides exhibiting low-micromolar blockade of MV fusion.
- One compound, AS-48, demonstrated potent activity with IC50 values ranging from 0.6 to 3.0 microM against various wild-type MV strains.
- MFTA analysis provided insights into structural features correlating with inhibitory potency, suggesting avenues for improvement.
Conclusions:
- Substituted anilides represent a promising class of nonpeptidic inhibitors for measles virus fusion.
- The identified lead compound AS-48 shows significant potential for further development as an anti-measles therapeutic.
- QSAR analysis can effectively guide the rational design of more potent measles virus entry inhibitors.
More Related Videos
Related Concept Videos
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Subviral Agents
Coronavirus

